AB BIOTICS SA
AB BIOTICS SA
AB Biotics S.A. | Date: 2017-01-18
A self-film-forming composition in powder form, a reconstituted formula and a kit for oral use are provided, which allow an adequate colonization of the probiotic in the oral cavities together with a sufficient residence time to allow beneficial effects against the pathogens related with oral conditions. Thus, the items provided are useful for the the prevention and/or treatment of a condition related to alterations of the oral microbiota, and specifically for peri-implantitis. The self-film-forming composition in powder form comprises at least a gelifier agent and/or at least a bioadhesive agent, and at least one lactic acid bacteria strain.
Fuentes M.C.,AB BIOTICS S.A. |
Lajo T.,Moncloa Hospital |
Carrion J.M.,Torrelodones University Hospital |
Cune J.,AB BIOTICS S.A.
British Journal of Nutrition | Year: 2013
Previous studies have indicated that supplementation with probiotic bacteria may improve lipid metabolism. The present study was aimed at investigating the effects of a mixture of three strains of Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) on cholesterol-lowering efficacy in hypercholesterolaemic patients. A total of sixty volunteers (thirty participants in the placebo group and thirty counterparts in the L. plantarum group), aged 18-65 years old, participated in a controlled, randomised, double-blind trial. The study group received one capsule daily containing 1.2 × 109 colony-forming units of Lactobacillus strains in a unique dose; the placebo group consumed the same product without bacteria for 12 weeks. A significant reduction of 13.6 % in plasma total cholesterol (TC) levels was observed after 12 weeks of consumption in the L. plantarum group when compared with the placebo group. The lipidic outcomes were also analysed based on TC values at baseline: low initial values (LIV, 2000-2500 mg/l) v. high initial values (HIV, 2510-3000 mg/l). In the HIV group, the L. plantarum treatment showed a reduction after 12 weeks of consumption compared with the placebo group in TC, LDL-cholesterol (LDL-C) and oxidised LDL-C (17.4, 17.6 and 15.6 %, respectively). In the LIV, the L. plantarum treatment only showed a reduction after 12 weeks of consumption when compared with the placebo group in TC (9.4 %). The present results showed that the biofunctionality of L. plantarum (CECT 7527, CECT 7528 and CECT 7529) is proportional to the cardiovascular risk of the patient, having a better effect in patients with higher levels of cholesterol. © 2012 The Authors.
Tuson M.,Sloan Kettering Institute |
Tuson M.,AB BIOTICS SA |
He M.,Sloan Kettering Institute |
He M.,Cornell University |
Anderson K.V.,Sloan Kettering Institute
Development | Year: 2011
Protein kinase A (PKA) is an evolutionarily conserved negative regulator of the hedgehog (Hh) signal transduction pathway. PKAis known to be required for the proteolytic processing event that generates the repressor forms of the Ci and Gli transcriptionfactors that keep target genes off in the absence of Hh. Here, we show that complete loss of PKA activity in the mouse leads tomidgestation lethality and a completely ventralized neural tube, demonstrating that PKA is as strong a negative regulator of thesonic hedgehog (Shh) pathway as patched 1 (Ptch1) or suppressor of fused (Sufu). Genetic analysis shows that although PKA isimportant for production of the repressor form of Gli3, the principal function of PKA in the Shh pathway in neural developmentis to restrain activation of Gli2. Activation of the Hh pathway in PKA mutants depends on cilia, and the catalytic and regulatorysubunits of PKA are localized to a compartment at the base of the primary cilia, just proximal to the basal body. The data showthat PKA does not affect cilia length or trafficking of smoothened (Smo) in the cilium. Instead, we find that there is a significantincrease in the level of Gli2 at the tips of cilia of PKA-null cells. The data suggest a model in which PKA acts at the base of thecilium after Gli proteins have transited the primary cilium; in this model the sequential movement of Gli proteins betweencompartments in the cilium and at its base controls accessibility of Gli proteins to PKA, which determines the fates of Gli proteinsand the activity of the Shh pathway. © 2011.
Ab Biotics S.A. | Date: 2010-09-28
The invention relates to a composition comprising an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527, Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529, These new strains have good probiotic features and are useful for the prevention and/or the treatment of cardiovascular disorders.
Ab Biotics S.A. | Date: 2015-05-05
The present invention provides a composition comprising an effective amount of Lactobacillus plantarum CECT 7481 and Lactobacillus brevis CECT 7480. Said strains exhibit various functional properties that make them suitable for their use in the improvement of oral health. Such properties include not only good antagonistic properties against oral pathogens, but also the ability to colonize the oral cavity and a low acidification profile. The invention also provides for the use of said composition as a probiotic and/or a medicament for oral health applications as well as products containing said composition.
AB Biotics S.A. | Date: 2014-12-10
The present invention relates to a web-based computer-aided method and a system for providing personalized recommendations about drug use, based on pharmacogenetic information regarding genes and genetic variants associated to metabolism and genes and genetic variants which are not associated to metabolism, and which comprises automatically generating and displaying, by means of a graphical user interface (GUI) of a dynamic webpage, the personalized recommendations highlighting the ones associated to the highest adverse drug reactions. The present invention also relates to a computer-readable medium which contains program instructions for a computer to perform the method for providing personalized recommendations about drug use of the invention. The present invention also relates to a web-based computer-aided method and a system for generating a dynamic webpage, and a further computer-readable medium which contains program instructions for a computer to perform the method for generating a dynamic webpage.
Ab Biotics S.A. | Date: 2016-04-21
The present disclosure is directed to methods of administering and compositions comprising Lactobacillus plantarum CECT 7478, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. The compositions and methods are useful in the probiotic treatment of bowel diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, and abdominal distension and bloating.
AB Biotics S.A. | Date: 2016-09-07
The new strains Lactobacillus plantarum CECT8675, CECT8676, CECT8677 and CECT8678 and mutants thereof are provided. The strains present as key advantage that they have the ability to antagonize the urogenital pathogens Staphylococcus saprophyticus, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis, which are useful in the management of UTI and other related conditions of the urogenital tract. Additionally, the strains of the present invention have the capacity to survive at high concentrations of fosfomycin, antibiotic typically used for managing UTI. In summary, the strains of the present invention can be co-administered with the antibiotic fosfomycin. The present invention also relates to the compositions and products comprising the new strains.
AB Biotics S.A. | Date: 2012-02-22
The present invention provides a composition comprising an effective amount of Lactobacillus plantarum strain CECT 7481 and Lactobacillus brevis strain CECT 7480. Said strains exhibit various functional properties that makes them suitable for their use in the improvement of oral health. Such properties include not only good antagonistic properties against oral pathogens, but also the ability to colonise the oral cavity and a low acidification profile The invention also provides for the use of said composition as a probiotic and/or a medicament for oral health applications as well as products containing said composition.
Ab Biotics S.A. and Venpharma Laboratorios | Date: 2014-08-07
Provided is a bacterial composition which comprises from 10^(4 )to 10^(12 )cfu/g of Pediococcus pentosaceus cells which have the ability to induce the production of interleukin-10 to reduce inflammation in the intestinal tract among other features and is useful in the amelioration of excessive crying in infants